ROS1 and central nervous system cancer: In pediatric gliomas and glioneuronal tumors, the ROS1 fusion, resulting from microdeletions at 6q22, has been identified as an oncogenic driver, highlighting the significance of ROS1 fusions in pediatric tumors [20].